Details of the Drug Combination

General Information of Drug Combination (ID: DC0WUY4)

Drug Combination Name
Sunitinib Carboplatin
Indication
Disease Entry Status REF
Small Cell Lung Cancer Phase 2 [1]
Component Drugs Sunitinib   DMCBJSR Carboplatin   DMG281S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sunitinib
Disease Entry ICD 11 Status REF
Acute undifferentiated leukemia N.A. Approved [2]
Chronic myelomonocytic leukemia N.A. Approved [2]
Classic Kaposi sarcoma N.A. Approved [2]
Gastrointestinal cancer 2C11 Approved [3]
Gastrointestinal stromal tumour 2B5B Approved [4]
Large granular lymphocytic leukemia 2A90.1 Approved [2]
Lung cancer 2C25.0 Approved [2]
Mast cell leukaemia 2A21.00 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Pancreatic cancer 2C10 Approved [2]
Primary myelofibrosis 2A20.2 Approved [2]
Prolymphocytic leukaemia 2A82.1 Approved [2]
Prostate adenocarcinoma N.A. Approved [2]
Refractory chronic myeloid leukaemia 2A20 Approved [2]
Salivary gland squamous cell carcinoma N.A. Approved [2]
Plexiform neurofibroma N.A. Investigative [2]
Sunitinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [7]
------------------------------------------------------------------------------------
Sunitinib Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [10]
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Sunitinib Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [13]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [13]
------------------------------------------------------------------------------------
Sunitinib Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases ADR [14]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases ADR [15]
------------------------------------------------------------------------------------
Indication(s) of Carboplatin
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [5]
Carcinoma 2A00-2F9Z Approved [5]
Cholangiocarcinoma 2C12.10 Approved [5]
Cutaneous melanoma 2C30 Approved [5]
Epithelial ovarian cancer 2B5D Approved [5]
Fallopian tube neoplasm N.A. Approved [5]
Gastroesophageal junction adenocarcinoma 2B71 Approved [5]
Lung adenocarcinoma N.A. Approved [5]
Lung cancer 2C25.0 Approved [5]
Non-small-cell lung cancer 2C25.Y Approved [5]
Ovarian cancer 2C73 Approved [6]
Ovarian disorder N.A. Approved [5]
Ovarian neoplasm N.A. Approved [5]
Ovarian serous cystadenocarcinoma N.A. Approved [5]
Small-cell lung cancer 2C25.Y Approved [5]
Lung large cell carcinoma N.A. Investigative [5]
Neuroblastoma 2D11.2 Investigative [5]
Carboplatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [16]
------------------------------------------------------------------------------------
Carboplatin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [17]
------------------------------------------------------------------------------------
Carboplatin Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [18]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [18]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Metabolism [18]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Metabolism [18]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Metabolism [18]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Metabolism [18]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Metabolism [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast Cancer DCNGANV N. A. Phase 1 [19]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00695292) Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
2 Sunitinib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5 Carboplatin FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
7 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
8 Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
9 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
10 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
11 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
12 In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
13 Drug Interactions Flockhart Table
14 Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics J. 2017 Jan;17(1):42-46. doi: 10.1038/tpj.2015.100. Epub 2016 Jan 26.
15 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
16 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
17 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
18 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
19 ClinicalTrials.gov (NCT00887575) Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer